Reza Mehdizadeh

Mr. Reza Mehdizadeh

Institute of Biochemistry and Biophysics (IBB), University of Tehran, Tehran, Iran
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
RMReza Mehdizadeh
Reza Mehdizadeh
SSSeyed Peyman Shariatpanahi
Seyed Peyman Shariatpanahi
BGBahram Goliaei
Bahram Goliaei
Curzio RueggCurzio Ruegg
Curzio Ruegg
Among the different breast cancer subsets, triple-negative breast cancer (TNBC) has the worst prognosis and limited options for targeted therapies. Immunotherapies are emerging as novel treatment opportunities for TNBC. However, the surging immune response elicited by immunotherapies to eradicate cancer cells can select resistant cancer cells, which may result in immune escape and tumor evolution and progression. Alternatively, maintaining the equilibrium phase of the immune response may be advantageous for keeping a long-term immune response in the presence of a small-size residual tumor. Myeloid-derived suppressor cells (MDSCs) are activated, expanded, and recruited to the tumor microenvironment by tumor-derived signals and can shape a pro-tumorigenic micro-environment by suppressing the innate and adaptive anti-tumor immune responses. We recently proposed a model describing immune-mediated breast cancer dormancy instigated by a vaccine consisting of dormant, immunogenic breast cancer cells derived from the murine 4T1 TNBC-like cell line. Strikingly, these 4T1-derived dormant cells recruited fewer MDSCs compared to aggressive 4T1 cells. Recent experimental studies demonstrated that inactivating MDSCs has a profound impact on reconstituting immune surveillance against the tumor. Here, we developed a deterministic mathematical model for simulating MDSCs depletion from mice bearing aggressive 4T1 tumors resulting in immunomodulation. Our computational simulations indicate that a vaccination strategy with a small number of tumor cells in combination with MDSC depletion can elicit an effective immune response suppressing the growth of a subsequent challenge with aggressive tumor cells, resulting in sustained tumor dormancy. The results predict a novel therapeutic opportunity based on the induction of effective anti-tumor immunity and tumor dormancy.

11 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
RMReza Mehdizadeh
Reza Mehdizadeh
SSSeyed Peyman Shariatpanahi
Seyed Peyman Shariatpanahi
BGBahram Goliaei
Bahram Goliaei
SPSanam Peyvandi
Sanam Peyvandi
Curzio RueggCurzio Ruegg
Curzio Ruegg
Triple-negative breast cancer (TNBC) is a molecular subtype of breast malignancy with a poor clinical prognosis. There is growing evidence that some chemotherapeutic agents induce an adaptive anti-tumor immune response. This reaction has been proposed to maintain the equilibrium phase of the immunoediting process and to control tumor growth by immunological cancer dormancy. We recently reported a model of immunological breast cancer dormancy based on the murine 4T1 TNBC model. Treatment of 4T1 cells in vitro with high-dose chemotherapy activated the type I interferon (type I IFN) signaling pathway, causing a switch from immunosuppressive to cytotoxic T lymphocyte-dependent immune response in vivo, resulting in sustained dormancy. Here, we developed a deterministic mathematical model based on the assumption that two cell subpopulations exist within the treated tumor: one population with high type I IFN signaling and immunogenicity and lower growth rate; the other population with low type I IFN signaling and immunogenicity and higher growth rate. The model reproduced cancer dormancy, elimination, and immune-escape in agreement with our previously reported experimental data. It predicted that the injection of dormant tumor cells with active type I IFN signaling results in complete growth control of the aggressive parental cancer cells injected at a later time point, but also of an already established aggressive tumor. Taken together, our results indicate that a dormant cell population can suppress the growth of an aggressive counterpart by eliciting a cytotoxic T lymphocyte-dependent immune response.

1 January 2017
Verified
Journal Article
Open access
MMMehrzad Mirzania
Mehrzad Mirzania
SSSeyed Reza Safaee
Seyed Reza Safaee
FSFarhad Shahi
Farhad Shahi
IJIssa Jahanzad
Issa Jahanzad
GZGhazal Zahedi
Ghazal Zahedi
RMReza Mehdizadeh
Reza Mehdizadeh
Background: Triple-negative breast cancers (TNBC) have a more aggressive course and are associated with poorer prognosis in comparison with other subtypes of breast cancer. One of the most common subtypes of TNBC is basal-like. The aim of this study was to investigate clinicopathological characteristics and clinical course of TNBC in Iranian women and compare them with other studies.

31 March 2012 in European Journal of Cancer
Verified
Journal Article
Closed access
PDF file
RMReza Mehdizadeh
Reza Mehdizadeh
SNS. Najafi
S. Najafi
IJI. Jahanzad
I. Jahanzad

29 November 2014
Verified
Closed access
PDF file
SNSafa Najafi
Safa Najafi
RMReza Mehdizadeh
Reza Mehdizadeh
EJEissa Jahanzad
Eissa Jahanzad
AOAsiie Olfatbakhsh
Asiie Olfatbakhsh
AJArash Jenabian
Arash Jenabian
MEMandana Ebrahimi
Mandana Ebrahimi